Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

progressive supranuclear palsy

This page shows the latest progressive supranuclear palsy news and features for those working in and with pharma, biotech and healthcare.

Spinraza lifts Biogen ahead of Alzheimer’s data

Spinraza lifts Biogen ahead of Alzheimer’s data

enrolment in phase 2 studies of new MS therapy opicinumab and BIIB092 for progressive supranuclear palsy.

Latest news

  • Celgene bulks up pipeline again with $2.1bn Prothena deal Celgene bulks up pipeline again with $2.1bn Prothena deal

    The three targets at the centre of the collaboration with Ireland-based Prothena include: tau protein, already a focus in Alzheimer’s research and other conditions like progressive supranuclear palsy (PSP);

  • AbbVie takes anti-tau drug into phase II for Alzheimer's AbbVie takes anti-tau drug into phase II for Alzheimer's

    drugs. The antibody - called ABBV-8E12 - is being tested in two phase II trials, one in patients with early Alzheimer's and a second in progressive supranuclear palsy (PSP), a rare ... We see potential in ABBV-8E12 and tau-focused approaches to

  • AbbVie and C2N take tau antibody into clinic AbbVie and C2N take tau antibody into clinic

    Treatment being assessed for a progressive neurodegenerative disorder. AbbVie and partner C2N have started clinical trials of an antibody targeting tau proteins that has just been granted orphan drug status by ... The first-in-class therapy - called

  • BMS buys Alzheimer's player iPierian in $725m deal BMS buys Alzheimer's player iPierian in $725m deal

    IPN007 is being developed in the first instance for progressive supranuclear palsy (PSP), a serious neurodegenerative disorder that progresses much more quickly than Alzheimer's but is also characterised by tau

  • CNS drug wins orphan status

    Drug-development company Mithridion has won orphan status from the US Food and Drug Administration for a potential treatment for brain disease progressive supranuclear palsy. ... The clinical-stage drug-development company Mithridion has won orphan

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Quick links

Infographics

Multimedia